Laparoscopy firm SurgRx attracts former Novacept backer in fundraising
This article was originally published in Clinica
Executive Summary
New Enterprise Associates, the long-established venture capital firm that backed Novacept through to its acquisition by Cytyc for $325m last year, has led a $21m investment round in SurgRx. Menlo Park, California-based SurgRx has developed an FDA-approved laparoscopic instrument, EnSeal, that operates via a radiofrequency controller and "Smart Electrode" sensor to cut and seal blood vessels and tissue while minimising thermal damage to adjacent tissue.